Top Markets
#1 Velas Velas +480.91%
#2 Siren Siren +109.58%
#3 NEW X CEO IS BACK NEW X CEO IS BACK +109.20%
#4 Venom Venom +45.46%
#5 Gigachad Gigachad +23.69%
#6 Ontology Ontology +20.18%
#7 Scor Scor +17.06%
#8 Dacxi Dacxi +16.49%
#9 Strategic Oil Supply Strategic Oil Supply +15.04%
#10 TRIA TRIA +14.71%
Coin of the day
Velas Velas
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
Peringkat dalam Saham #17276
Noxopharm Limited, a drug development company, focuses on developing treatment... Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
Harga Saham
$0.0416118
Kapitalisasi Pasar
$12.78M
Perubahan (1 hari)
1.72%
Perubahan (1 tahun)
-22.01%
Negara
AU
Perdagangan Noxopharm Limited (NOX)

Kategori

Healthcare
Rasio P/E untuk Noxopharm Limited (NOX)
Rasio P/E per March 2026 TTM: -3.25
Menurut laporan keuangan dan harga saham terbaru dari Noxopharm Limited, rasio P/E saat ini (TTM) adalah -3.25. Pada akhir 2024, perusahaan memiliki rasio P/E sebesar -5.39.
Riwayat rasio P/E untuk Noxopharm Limited dari 2016 hingga 2026
Rasio P/E di akhir setiap tahun
Tahun Rasio P/E Mengubah
2026 (TTM) -3.25 0.53%
2025 -3.23 -40.02%
2024 -5.39 545.91%
2023 -0.83 -72.57%
2022 -3.04 -83.29%
2021 -18.21 -78.30%
2020 -83.90 1,577.80%
2019 -5.00 42.59%
2018 -3.51 -62.16%
2017 -9.27 19.11%
2016 -7.78 0.00%
Rasio P/E untuk perusahaan serupa atau pesaing
Perusahaan Rasio P/E Perbedaan Rasio P/E Negara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 10.72 -430.04%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 30.14 -1,028.31%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 17.03 -624.60%
US
UCB SA UCB SA
UCB SA
UCB.BR
 30.44 -1,037.38%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 33.07 -1,118.52%
AU
Bagaimana cara membaca P/E ratio?

Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.

Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.

Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.